Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Invesco Nasdaq Biotechnology ETF(IBBQ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IBBQ
10/28/2026: IBBQ (2-star) is currently NOT-A-BUY. Pass it for now.
The Invesco Nasdaq Biotechnology ETF (IBBQ) offers investors a cost-efficient vehicle to gain exposure to the biotechnology and pharmaceutical sectors by tracking the Nasdaq Biotechnology Index. Its main strength lies in its low expense ratio and institutional-grade management under the Invesco brand, making it a viable alternative for investors seeking benchmark-matched exposure. The fund is best suited for growth-oriented retail investors looking for long-term sector participation, though it carries high risks related to sector concentration, clinical trial failure, and drug-pricing policy. Investors should monitor FDA trends, M&A activity, and interest rate changes as key drivers of performance in this high-volatility sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The biotechnology sector is a quintessential growth industry driven by innovation and high-risk/high-reward clinical outcomes. |
| Momentum investor | Strong fit while signal remains positive | Biotech stocks often exhibit strong multi-month momentum trends based on drug trial data and regulatory announcements. |
| Value investor | Weak fit | Biotech firms are frequently unprofitable or trading at high multiples, making them a poor fit for traditional value screens. |
| Dividend/Income investor | Weak fit | Most constituents in this sector reinvest capital into R&D rather than paying dividends to shareholders. |
| Low-risk investor | Weak fit | The sector's inherent volatility and binary risk make it unsuitable for conservative, capital-preservation focused portfolios. |
Investor Profile
Ideal Investor Profile
Investors seeking targeted, cost-efficient exposure to the biotechnology sector who have a high tolerance for risk and a long-term time horizon.
Suitability
Best suited for growth-oriented investors looking for core or satellite exposure to biotech; less suitable for conservative or income-seeking investors.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The biotech industry is prone to sharp price swings based on clinical trial results and binary regulatory events. |
| Market risk | Medium / high | The fund is subject to general equity market downturns, which often trigger a 'risk-off' trade in biotech stocks. |
| Concentration | High | The index is concentrated in a single sector, meaning firm-specific issues can disproportionately impact the total return. |
| Tracking/expense | Low | The fund is efficiently managed with a low expense ratio and minimal tracking error against its index. |
| Liquidity | Medium | While the fund is liquid, smaller biotech holdings may suffer from wider spreads during periods of market stress. |
| Business/sector quality | Medium / high | The sector relies on long-term R&D success and regulatory approval, which are inherently uncertain business models. |
Risk Analysis
Volatility
IBBQ exhibits high historical volatility, consistent with the specialized nature of the biotechnology industry.
Market Risk
The fund faces concentrated risk; it is susceptible to sector-specific regulatory, clinical, and economic shocks.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Biotechnology | 75 | This provides core exposure to clinical-stage and commercial-stage biotech firms focused on innovative drug development. |
| Industry | Pharmaceuticals | 20 | Includes established pharmaceutical companies often characterized by more stable cash flows compared to pure-play biotech. |
| Cash/collateral | Cash and Cash Equivalents | 5 | Represents minor liquidity held for daily fund operations and rebalancing. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 49.92% | Avg. Invested days 84 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.